A greater understanding of the complexity of breast cancer, in all its forms, is key to better patient selection, new target development and improved outcomes, says Prof. Fabrice André
Early-phase trials suggest that sitravatinib may reboot the tumour response to PD-1 inhibitors, but confirmation of efficacy is required and strategies are needed to adjust tolerability
Over the last decade, much progress has been made in developing a range of antibody–drug conjugates to treat breast cancer, with the construction of bespoke agents for individual patients and exciting prospect for the future
Ensuring equitable access to innovative treatments is now the major challenge in oncology, says Prof. Alex Adjei
Shared interests, mutual gain, flexibility and trust are key to building win–win partnerships in drug development.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.